Background: Breast cancer is one of the most common malignancies among Iranian women; however, its clinicopathological feature is uncertain. We pioneered a genetic counseling program among patients with breast cancer and their families in Isfahan. This is the first report of this program. Methods: This was a descriptive cross-sectional study on women with breast cancer registered in Ala Cancer...

BACKGROUND Expression of hormone receptors is routinely evaluated in predicting tumor response to hormone therapy in breast cancer patients. Normal female genital organs show cyclic changes in the expression of estrogen and progesterone receptors. This study was designed to assess variations in estrogen and progesterone receptor expression rates in breast cancer patients, who were operated in d...

BACKGROUND It has been suggested that a low level of the 2-hydroxyestrogen metabolites (2-OHE) and a high level of 16alpha-hydroxyestrone (16alpha-OHE1) are associated with an enhanced risk of breast cancer. We examined the association between the metabolite levels and breast cancer in a nested case-control study, which also addressed hormone replacement therapy (HRT) and estrogen receptor stat...

Recently, we identified a novel breast cancer susceptibility locus at 6q22.33 following a genome-wide association study in the Ashkenazi Jewish genetic isolate. To replicate these findings, we did a case-control association analysis on 6q22.33 (rs2180341) in an additional 487 Ashkenazi Jewish breast cancer cases and in an independent non-Jewish, predominantly European American, population of 1,...

Cervical cancer (CC) is the fourth most common cause of death among women globally. Nearly 90% CC mortality occurs in low- and middle-income countries. Hence there an urgent need for identification new biomarkers early diagnosis treatment CC. Current research aims to investigate effect mechanism estrogen receptor 1 aurora kinase A as potential diagnostic cervical cancer. Gene microarray dataset...

Triple-negative breast cancer (TNBC) is considered one of the most aggressive forms with poor survival rates compared to other subtypes. TNBC characterized by absence estrogen receptor alpha, progesterone receptor, and human epidermal growth factor 2, limiting those viable treatment options available patients Furthermore, due particularly high heterogeneity TNBC, conventional treatments such as...

Estrogen-receptor antagonists are used in the therapy of estrogen-responsive diseases including breast cancer and endometrial cancer. Tamoxifen, the non-steroidal estrogen-receptor antagonist, is now the first choice of anti-hormonal treatment for advanced breast cancer. In spite of its effectiveness, the long-term use of tamoxifen frequently results in tumor resistance to itself and its relate...

The measurement of cytoplasmic estrogen receptor in tumors from patients with breast cancer is now well established. Potential uses include prognosis of early recurrence following mastectomy, stratifying patients for adjuvant therapies, and selecting or rejecting endocrine therapy in advanced breast cancer. The use of progesterone receptor measurements to improve our selection process has a goo...

The cytoplasmic estrogen receptor was measured in 9 intracranial meningiomas and 8 thymomas. The binding affinities of the estrogen receptor derived from the tumors to various estrogens and antiestrogens were compared with that observed for the receptor from rat normal uterus. The cytoplasmic progesterone receptor was measured concomitantly. The estrogen receptor was positive in 4 and 3 cases o...